Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study - Takeaways - MDSpire

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • By

  • Shigenori Kadowaki

  • Tomoyuki Otsuka

  • Keiko Minashi

  • Shinichi Nishina

  • Hiroshi Yabusaki

  • Chiaki Inagaki

  • Tomohiro Nishina

  • Hisateru Yasui

  • Hiroshi Matsuoka

  • Nozomu Machida

  • Masahiro Tsuda

  • Fumio Nagashima

  • Hisashi Hosaka

  • Junichi Matsubara

  • Hiroyuki Arai

  • Satoshi Ida

  • Yuya Kimijima

  • Yuko Matsuda

  • Manabu Muto

  • Kei Muro

  • June 18, 2026

  • 0 min

Share

  • 1

    The article presents a correction to the G-KNIGHT study on nivolumab and chemotherapy for gastric cancer.

  • 2

    The overall response rate (ORR) was reported as 65.6% with a disease control rate (DCR) of 91.6% among 299 patients.

  • 3

    Out of the patients evaluated, 2.7% achieved a complete response, 62.9% had a partial response, and 26.1% had stable disease.

  • 4

    The correction addresses inaccuracies in Table 3 and Figure 2 regarding stable disease, progressive disease, and DCR values.

  • 5

    The corrected data is essential for accurate interpretation of the study's findings on treatment efficacy.

Original Source(s)

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • by Shigenori Kadowaki, Tomoyuki Otsuka, Keiko Minashi, Shinichi Nishina, Hiroshi Yabusaki, Chiaki Inagaki, Tomohiro Nishina, Hisateru Yasui, Hiroshi Matsuoka, Nozomu Machida, Masahiro Tsuda, Fumio Nagashima, Hisashi Hosaka, Junichi Matsubara, Hiroyuki Arai, Satoshi Ida, Yuya Kimijima, Yuko Matsuda, Manabu Muto, Kei Muro

  • June 18, 2026

Related Content

Active surveillance or surgical resection? A survey of treatment strategies for low-risk papillary thyroid microcarcinoma in adults

Temporal dynamics and determinants of early recurrence after curative resection for stage I-III rectal cancer: integrated analyses of hazard function, survival, and competing risks

Concordant ETV6::RUNX1-positive acute lymphoblastic leukemia in monozygotic twins: a case report and review of the literature